Skip to main content

Advertisement

SpringerLink
Log in

Pulmonary Arterial Hypertension and the Sex Hormone Paradox

  • Pulmonary Hypertension (J Klinger, Section Editor)
  • Published:
Current Hypertension Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

Prevalence and outcome differences between women and men with pulmonary arterial hypertension (PAH) raise questions about the role of sex hormones in disease pathobiology. This review will summarize the current understanding of sex and sex hormone pathways and their influence on heart-lung function in health and in disease.

Recent Findings

Female sex has been shown to be a risk factor for the development of PAH, but women have improved survival compared to men with PAH. These paradoxical observations are likely driven in part by complex sex hormone signaling and processing pathways and their interaction with the pulmonary vasculature and the right ventricle. These relationships may vary depending on an individual’s underlying sex, age, and/or genetic substrate.

Summary

The study of the connections between sex, sex hormones, the pulmonary circulation, and the right ventricle may improve our understanding of disease epidemiology and outcomes and lead to new treatment strategies for PAH.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. Dresdale DT, Schultz M, Michtom RJ. Primary pulmonary hypertension: I. Clinical and hemodynamic study. Am J Med. 1951;11(6):688–705.

    Article  Google Scholar 

  2. Rich S, Dantzker DR, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, et al. Primary pulmonary hypertension. Ann Intern Med. 1987;107(216–223).

  3. Olsson KM, Delcroix M, Ghofrani HA, Tiede H, Huscher D, Speich R, et al. Anticoagulation and survival in pulmonary arterial hypertension: results from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA). Circulation. 2014;129(1):57–65.

    Article  CAS  PubMed  Google Scholar 

  4. Ling Y, Johnson MK, Kiely DG, Condliffe R, Elliot CA, Gibbs JS, et al. Changing demographics, epidemiology, and survival of incident pulmonary arterial hypertension: results from the pulmonary hypertension registry of the United Kingdom and Ireland. Am J Respir Crit Care Med. 2012;186(8):790–6.

    Article  PubMed  Google Scholar 

  5. Frost AE, Badesch DB, Barst RL, Elliott CG, Farber HW, Krichman A, et al. The changing picture of patients with pulmonary arterial hypertension in the United States: how REVEAL differs from historic and non-US Contemporary Registries. Chest. 2011;139(1):128–37.

    Article  PubMed  Google Scholar 

  6. Chung L, Liu J, Parsons L, Hassoun PM, McGoon M, Badesch DB, et al. Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL: identifying systemic sclerosis as a unique phenotype. Chest. 2010;138(6):1383–94.

    Article  PubMed  PubMed Central  Google Scholar 

  7. • Hoeper MM, Huscher D, Ghofrani HA, Delcroix M, Distler O, Schweiger C, et al. Elderly patients diagnosed with idiopathic pulmonary arterial hypertension: results from the COMPERA registry. Int J Cardiol. 2013;168(2):871–80. This registry raises interesting questions regarding how age plays a role in the interaction between sex hormones and PAH. The female:male ratio was 2.3:1 among 18–65 year olds but nearly even 1.2:1 among those older than 65.

    Article  PubMed  Google Scholar 

  8. Peacock AJ, Murphy NF, McMurray JJ, Caballero L, Stewart S. An epidemiological study of pulmonary arterial hypertension. Eur Respir J. 2007;30(1):104–9.

    Article  CAS  PubMed  Google Scholar 

  9. Benza RL, Miller DP, Barst RJ, Badesch DB, Frost AE, McGoon MD. An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry. Chest. 2012;142(2):448–56.

    Article  PubMed  Google Scholar 

  10. Farber HW, Miller DP, Poms AD, Badesch DB, Frost AE, Muros-Le Rouzic E, et al. Five-year outcomes of patients enrolled in the REVEAL Registry. Chest. 2015;148(4):1043–54.

    Article  PubMed  Google Scholar 

  11. Krowka MJ, Miller DP, Barst RJ, Taichman D, Dweik RA, Badesch DB, et al. Portopulmonary hypertension: a report from the US-based REVEAL Registry. Chest. 2012;141(4):906–15.

    Article  PubMed  Google Scholar 

  12. Lee WT, Ling Y, Sheares KK, Pepke-Zaba J, Peacock AJ, Johnson MK. Predicting survival in pulmonary arterial hypertension in the UK. Eur Respir J. 2012;40(3):604–11.

    Article  PubMed  Google Scholar 

  13. Benza RL, Miller DP, Gomberg-Maitland M, Frantz RP, Foreman AJ, Coffey CS, et al. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation. 2010;122(2):164–72.

    Article  PubMed  Google Scholar 

  14. Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V, et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med. 2006;173(9):1023–30.

    Article  PubMed  Google Scholar 

  15. • Badesch DB, Raskob GE, Elliott CG, Krichman AM, Farber HW, Frost AE, et al. Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. Chest. 2010;137(2):376–87. This is the largest US PAH registry to date and reported a more pronounced sex bias than other registries. This raises the question whether there has been a true change in disease biology or whether the predominantly prevalent study population skews the bias, especially given a survival bias conferred by female sex.

    Article  PubMed  Google Scholar 

  16. McGoon MD, Benza RL, Escribano-Subias P, Jiang X, Miller DP, Peacock AJ, et al. Pulmonary arterial hypertension: epidemiology and registries. J Am Coll Cardiol. 2013;62(25 Suppl):D51–9.

    Article  PubMed  Google Scholar 

  17. Jing ZC, Xu XQ, Han ZY, Wu Y, Deng KW, Wang H, et al. Registry and survival study in Chinese patients with idiopathic and familial pulmonary arterial hypertension. Chest. 2007;132(2):373–9.

    Article  PubMed  Google Scholar 

  18. Benza RL, Gomberg-Maitland M, Miller DP, Frost A, Frantz RP, Foreman AJ, et al. The REVEAL Registry risk score calculator in patients newly diagnosed with pulmonary arterial hypertension. Chest. 2012;141(2):354–62.

    Article  PubMed  Google Scholar 

  19. Barst RJ, McGoon MD, Elliott CG, Foreman AJ, Miller DP, Ivy DD. Survival in childhood pulmonary arterial hypertension: insights from Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management. Circulation. 2012;125:113–22.

    Article  PubMed  Google Scholar 

  20. Humbert M, Sitbon O, Yaici A, Montani D, O’Callaghan DS, Jais X, et al. Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension. Eur Respir J. 2010;36(3):549–55.

    Article  CAS  PubMed  Google Scholar 

  21. D’Alonzo GE, Barst RJ, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med. 1991;115(5):343–9.

    Article  PubMed  Google Scholar 

  22. Thenappan T, Shah SJ, Rich S, Tian L, Archer SL, Gomber-Maitland M. Survival in pulmonary arterial hypertension: a reappraisal of the NIH risk stratification equation. Eur Respir J. 2010;35(5):1079–87.

    Article  CAS  PubMed  Google Scholar 

  23. Escribano-Subias P, Blanco I, Lopez-Meseguer M, Lopez-Guarch CJ, Roman A, Morales P, et al. Survival in pulmonary hypertension in Spain: insights from the Spanish registry. Eur Respir J. 2012;40(3):596–603.

    Article  PubMed  Google Scholar 

  24. Zhang R, Dai LZ, Xie WP, Yu ZX, Wu BX, Pan L, et al. Survival of Chinese patients with pulmonary arterial hypertension in the modern treatment era. Chest. 2011;140(2):301–9.

    Article  PubMed  Google Scholar 

  25. Walker AM, Langleben D, Korelitz JJ, Rich S, Rubin LJ, Strom BL, et al. Temporal trends and drug exposures in pulmonary hypertension: an American experience. Am Heart J. 2006;152(3):521–6.

    Article  CAS  PubMed  Google Scholar 

  26. Kane GC, Maradit-Kremers H, Slusser JP, Scott CG, Frantz RP, McGoon MD. Integration of clinical and hemodynamic parameters in the prediction of long-term survival in patients with pulmonary arterial hypertension. Chest. 2011;139(6):1285–93.

    Article  PubMed  Google Scholar 

  27. Loyd JE, Butler MG, Foroud TM, Conneally PM, Phillips JA, Newman JH. Genetic anticipation and abnormal gender ratio at birth in familial primary pulmonary hypertension. Am J Respir Crit Care Med. 1995;152:93–7.

    Article  CAS  PubMed  Google Scholar 

  28. Evans JD, Girerd B, Montani D, Wang XJ, Galiè N, Austin ED, et al. BMPR2 mutations and survival in pulmonary arterial hypertension: an individual participant data meta-analysis. Lancet Respir Med. 2016;4(2):129–37.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Chung L, Farber HW, Benza R, Miller DP, Parsons L, Hassoun PM, et al. Unique predictors of mortality in patients with pulmonary arterial hypertension associated with systemic sclerosis in the REVEAL registry. Chest. 2014;146(6):1494–504.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Kawut SM, Krowka MJ, Trotter JF, Roberts KE, Benza RL, Badesch DB. Clinical risk factors for portopulmonary hypertension. Hepatology. 2008;48(1):196–203.

    Article  PubMed  PubMed Central  Google Scholar 

  31. • Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V, et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation. 2010;122(2):156–63. This study demonstrated male sex to be a risk factor for death within a population of idiopathic, familial, and anorexigen-associated PAH patients in the French PAH registry.

    Article  PubMed  Google Scholar 

  32. Shapiro S, Traiger GL, Turner M, McGoon MD, Wason P, Barst RJ. Sex differences in the diagnosis, treatment, and outcome of patients with pulmonary arterial hypertension enrolled in the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management. Chest. 2012;141(2):363–73.

    Article  PubMed  Google Scholar 

  33. Chung L, Domsic RT, Lingala B, Alkassab F, Boster M, Csuka ME, et al. Survival and predictors of mortality in systemic sclerosis-associated pulmonary arterial hypertension: outcomes from the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma Registry. Arthritis Care Res. 2014;66(3):489–95.

    Article  Google Scholar 

  34. Kawut SM, Barr RG, Lima JA, Praestgaard A, Johnson WC, Chahal H, et al. Right ventricular structure is associated with the risk of heart failure and cardiovascular death: the Multi-Ethnic Study of Atherosclerosis (MESA)–Right Ventricle Study. Circulation. 2012;126(14):1681–8.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Kawut SM, LIma JA, Barr RG, Chanal H, Jain A, Tandri H, et al. Sex and race differences in right ventricular structure and function: the Multi-Ethnic Study of Atherosclerosis-Right Ventricle Study. Circulation. 2011;123(22):2542–51.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Foppa M, Arora G, Gona P, Ashrafi A, Salton CJ, Yeon SB, et al. Right ventricular volumes and systolic function by cardiac magnetic resonance and the impact of sex, age, and obesity in a longitudinally followed cohort free of pulmonary and cardiovascular disease: The Framingham Heart Study. Circ Cardiovasc Imaging. 2016;9(3):e003810.

    Article  PubMed  Google Scholar 

  37. Ventetuolo CE, Ouyang P, Bluemke DA, Tandri H, Barr RG, Bagiella E, et al. Sex hormones are associated with right ventricular structure and function: the MESA-Right Ventricle Study. Am J Respir Crit Care Med. 2011;183(5):659–67.

    Article  PubMed  Google Scholar 

  38. • Ventetuolo CE, Mitra N, Wan F, Manichaikul A, Barr RG, Johnson C, et al. Oestradiol metabolism and androgen receptor genotypes are associated with right ventricular function. Eur Respir J. 2016;47(2):553–63. This is the first and only genotype-phenotype association study for the right ventricle. Polymorphisms in estradiol metabolism were tied to right ventricular function in healthy post-menopausal women, while genetic variation in the androgen receptor was associated with right heart morphology in healthy men from the Multi-Ethnic Study of Atherosclerosis cohort.

    Article  PubMed  Google Scholar 

  39. • Austin ED, Cogan JD, West JD, Hedges LK, Hamid R, Dawson EP, et al. Alterations in oestrogen metabolism: implications for higher penetrance of familial pulmonary arterial hypertension in females. Eur Respir J. 2009;34(5):1093–9. This study is the first to link genetic variation in sex hormone genes (CYP1B1, the major enzyme responsible for estradiol metabolism), to penetrance in heritable PAH.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Diergaarde B, Potter JD, Jupe ER, Manjeshwar S, Shimasaki CD, Pugh TW, et al. Polymorphisms in genes involved in sex hormone metabolism, estrogen plus progestin hormone therapy use, and risk of postmenopausal breast cancer. Cancer Epidemiol Biomarkers Prev. 2008;17(7):1751–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Kato I, Cichon M, Yee CL, Land S, Korczak JF. African American-preponderant single nucleotide polymorphisms (SNPs) and risk of breast cancer. Cancer Epidemiol. 2009;33(1):24–30.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Paracchini V, Raimondi S, Gram IT, Kang D, Kocabas NA, Kristensen VN, et al. Meta- and pooled analyses of the cytochrome P-450 1B1 Val432Leu polymorphism and breast cancer: a HuGE-GSEC review. Am J Epidemiol. 2007;165(2):115–25.

    Article  PubMed  Google Scholar 

  43. Wenzlaff AS, Cote ML, Bock CH, Land SJ, Santer SK, Schwartz DR, et al. CYP1A1 and CYP1B1 polymorphisms and risk of lung cancer among never smokers: a population-based study. Carcinogenesis. 2005;26(12):2207–12.

    Article  CAS  PubMed  Google Scholar 

  44. van de Veerdonk MC, Kind T, Marcus JT, Mauritz GJ, Heymans MW, Bogaard HJ, et al. Progressive right ventricular dysfunction in patients with pulmonary arterial hypertension responding to therapy. J Am Coll Cardiol. 2011;58(24):2511–9.

    Article  PubMed  Google Scholar 

  45. van Wolferen SA, van de Veerdonk MC, Mauritz GJ, Jacobs W, Marcus JT, Marques KM, et al. Clinically significant change in stroke volume in pulmonary hypertension. Chest. 2011;139(5):1003–9.

    Article  PubMed  Google Scholar 

  46. van Wolferen SA, Marcus JT, Boonstra A, Marques KM, Bronzwaer JG, Spreeuwenberg MD, et al. Prognostic value of right ventricular mass, volume, and function in idiopathic pulmonary arterial hypertension. Eur Heart J. 2007;28(10):1250–7.

    Article  PubMed  Google Scholar 

  47. Kawut SM, Al-Naamani N, Agerstrand C, Rosenzweig EB, Rowan C, Barst RJ, et al. Determinants of right ventricular ejection fraction in pulmonary arterial hypertension. Chest. 2009;135(3):752–9.

    Article  PubMed  Google Scholar 

  48. • Jacobs W, Van de Veerdonk MC, Trip P, de Man F, Heymans MW, Marcus JT, et al. The right ventricle explains sex differences in survival in idiopathic pulmonary arterial hypertension. Chest. 2014;145(6):1230–6. This study demonstrates that PAH treatment-induced changes in right ventricular ejection fraction explain a significant proportion of the survival differences between men and women with PAH.

    Article  PubMed  Google Scholar 

  49. Forte P, Kneale BJ, Milne E, Chowienczyk PJ, Johnston A, Benjamin N, et al. Evidence for a difference in nitric oxide biosynthesis between healthy women and men. Hypertension. 1998;32(4):730–4.

    Article  CAS  PubMed  Google Scholar 

  50. Miyauchi T, Yanagisawa M, Lida K, Ajisaka R, Suzuki N, Fujino M, et al. Age- and sex-related variation of plasma endothelin-1 concentration in normal and hypertensive subjects. Am Heart J. 1992;123(4):1092–3.

    Article  CAS  PubMed  Google Scholar 

  51. Stauffer BL, Westby CM, Greiner JJ, Van Guilder GP, Desouza CA. Sex differences in endothelin-1-mediated vasoconstrictor tone in middle-aged and older adults. Am J Physiol Regul Integr Comp Physiol. 2010;298(2):R261–5.

    Article  CAS  PubMed  Google Scholar 

  52. Billon-Gales A, Fontaine C, Filipe C, Douin-Echinard V, Fouque MJ, Flouriot G, et al. The transactivating function 1 of estrogen receptor alpha is dispensable for the vasculoprotective actions of 17beta-estradiol. Proc Natl Acad Sci U S A. 2009;106(6):2053–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Polderman KH, Stehouwer CD, van Kamp GJ, Dekker GA, Verheugt FW, Gooren LJ. Influence of sex hormones on plasma endothelin levels. Ann Intern Med. 1993;118(6):429–32.

    Article  CAS  PubMed  Google Scholar 

  54. Russell KS, Haynes MP, Sinha D, Clerisme E, Bender JR. Human vascular endothelial cells contain membrane binding sites for estradiol, which mediate rapid intracellular signaling. Proc Natl Acad Sci U S A. 2000;97(11):5930–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Gabler NB, French B, Strom BL, Liu Z, Palevsky HI, Taichman DB, et al. Race and sex differences in response to endothelin receptor antagonists for pulmonary arterial hypertension. Chest. 2012;141(1):20–6.

    Article  CAS  PubMed  Google Scholar 

  56. Mathai SC, Hassoun PM, Puhan MA, Zhou Y, Wise RA. Sex differences in response to tadalafil in pulmonary arterial hypertension. Chest. 2015;147(1):188–97.

    Article  PubMed  Google Scholar 

  57. • Lahm T, Tuder RM, Petrache I. Progress in solving the sex hormone paradox in pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol. 2014;307(1):L7–26. This review article details the preclinical evidence linking sex hormones to pulmonary vascular disease pathobiology.

    Article  CAS  PubMed  Google Scholar 

  58. Deng Z, Morse JH, Slager SL, Cuervo N, Moore KJ, Venetos G, et al. Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. Am J Hum Genet. 2000;67(3):737–44.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Soubrier F, Chung WK, Machado R, Grunig E, Aldred M, Geraci M, et al. Genetics and genomics of pulmonary arterial hypertension. J Am Coll Cardiol. 2013;62(25 Suppl):D13–21.

    Article  CAS  PubMed  Google Scholar 

  60. Dubey RK, Jackson EK, Gillespie DG, Rosselli M, Barchiesi F, Krust A, et al. Cytochromes 1A1/1B1- and catechol-O-methyltransferase-derived metabolites mediate estradiol-induced antimitogenesis in human cardiac fibroblast. J Clin Endocrinol Metab. 2005;90(1):247–55.

    Article  CAS  PubMed  Google Scholar 

  61. Austin ED, Hamid R, Hemnes AR, Loyd JE, Blackwell T, Yu C, et al. BMPR2 expression is suppressed by signaling through the estrogen receptor Biol Sex Differ. 2012;3(1).

  62. White K, Johansen AK, Nilsen M, Ciuclan L, Wallace E, Paton L, et al. Activity of the estrogen-metabolizing enzyme cytochrome P450 1B1 influences the development of pulmonary arterial hypertension. Circulation. 2012;126(9):1087–98.

    Article  CAS  PubMed  Google Scholar 

  63. Roberts KE, Fallon MB, Krowka MJ, Brown RS, Trotter JF, Peter I, et al. Genetic risk factors for portopulmonary hypertension in patients with advanced liver disease. Am J Respir Crit Care Med. 2009;179(9):835–42.

    Article  PubMed  PubMed Central  Google Scholar 

  64. • Ventetuolo CE, Baird GL, Barr RG, Bluemke DA, Fritz JS, Hill NS, et al. Higher estradiol and lower dehydroepiandrosterone-sulfate levels are associated with pulmonary arterial hypertension in men. Am J Respir Crit Care Med. 2016;193(10):1168–75. This is the first study to demonstrate that sex hormone levels are associated with the risk of PAH in men. Surprisingly, high estradiol levels in men (and low dehydroepiandrosterone-sulfate levels) conferred an increased risk of PAH and greater disease severity.

    Article  PubMed  Google Scholar 

  65. Mair KM, Wright AF, Duggan N, Rowlands DJ, Hussey MJ, Roberts S, et al. Sex-dependent influence of endogenous estrogen in pulmonary hypertension. Am J Respir Crit Care Med. 2014;190(4):456–67.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  66. Wright AF, Ewart MA, Mair K, Nilsen M, Dempsie Y, Loughlin L, et al. Oestrogen receptor alpha in pulmonary hypertension. Cardiovasc Res. 2015;106(2):206–16.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  67. Dean A, Nilsen M, Loughlin L, Salt IP, MacLean MR. Metformin reverses development of pulmonary hypertension via aromatase inhibition. Hypertension. 2016;68(2):446–54.

    Article  CAS  PubMed  Google Scholar 

  68. • Kawut SM, Archer-Chicko CL, Dimichele A, Fritz JS, Klinger RJ, Ky B, et al. Anastrozole in pulmonary arterial hypertension (AIPH): a randomized, double-blind placebo-controlled trial. Am J Respir Crit Care Med. 2016. This randomized control trial showed that anastrazole significantly reduced estradiol levels and improved 6MWD. Although a pilot study, it demonstrates the feasibility of hormonal manipulation as a treatment strategy in PAH.

Download references

Author information

Authors and Affiliations

  1. Division of Pulmonary, Critical Care and Sleep, Brown University, Providence, RI, USA

    Andrew Foderaro & Corey E. Ventetuolo

  2. Department of Medicine, Brown University, Providence, RI, USA

    Andrew Foderaro & Corey E. Ventetuolo

  3. Health Services, Policy, and Practice, Brown University, Providence, RI, USA

    Corey E. Ventetuolo

Authors
  1. Andrew Foderaro
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Corey E. Ventetuolo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Corey E. Ventetuolo.

Ethics declarations

Conflict of Interest

The authors declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Pulmonary Hypertension

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Foderaro, A., Ventetuolo, C.E. Pulmonary Arterial Hypertension and the Sex Hormone Paradox. Curr Hypertens Rep 18, 84 (2016). https://doi.org/10.1007/s11906-016-0689-7

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11906-016-0689-7

Keywords

Search

Navigation